ClinicalTrials.gg
TerminatedNCT04161885VIALE-TUpdated Jun 4, 2026Results posted

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

A Phase 3 interventional study of Venetoclax and Azacitidine in Acute Myeloid Leukemia (AML) and Cancer, sponsored by AbbVie. Terminated at 165 sites in 18 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Why this study was terminated
Strategic considerations

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
465
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 202 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 144 under way, 21 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.

Enrollment
9th of 202
465 · median 57
Started
2020
with 15 others
Phase 3
16 of 202
7 open now
Registered
41st of 202
by date
Lead sponsor
15 of 202
AbbVie

Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 9th largest by enrollment, is one of 16 that started in 2020, is one of 16 in phase 3, and was the 41st registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

116 of the 202 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

111 more — sign in →

By country, each count listing its studies:

All 116 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies testing venetoclax in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when given as maintenance therapy following allogeneic stem cell transplantation (SCT).

This study will have 2 parts: Part 1 (Dose Confirmation), which may include participants who are greater than or equal to 18 years old; Part 2 (Randomization) which may include participants who are greater than or equal to 12 years old. During Part 1, recommended Phase 3 dose of venetoclax in combination with azacitidine will be determined and during Part 2, the efficacy and safety of venetoclax with azacitidine (Part 2 Arm A) will be compared with BSC (Part 2 Arm B).

03

Conditions studied

  • Acute Myeloid Leukemia (AML)
  • Cancer

Keywords

  • Acute Myeloid Leukemia (AML)
  • Venetoclax
  • Azacitidine
  • Stem Cell Transplantation (SCT)
  • Best Support Care (BSC)
  • Cancer
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be at least 18 years old for Part 1 and, at least 12 years old for Part 2.
  • Participant must be diagnosed with Acute Myeloid Leukemia (AML) by World Health Organization (WHO) criteria (2017) and either be planning for stem cell transplantation or have received allogeneic stem cell transplantation within the past 60 days.
  • Blast percentage in bone marrow before transplant must be \< 10%.
  • Blast count in peripheral blood must be "0" and Blast percentage in bone marrow must be \< 5% after transplant.
  • Participant meet adequate renal, hepatic and hematologic criteria as described in the protocol.
  • Participants >= 17 years old must have a Performance Scale (KPS) score > 50 and participants between 12 to 16 years old must have a Lansky Play Performance Scale score > 40.

Exclusion criteria

Exclusion Criteria:

  • History of disease progression during prior treatment with venetoclax.
  • History of any other within 2 years prior to study entry, except for: Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast; basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; previous malignancy confined and surgically resected (or treated with other modalities) with curative intent; Myelodysplastic Syndrome, Myeloproliferative neoplasm (only allowed if it transformed to AML and AML should be the indication for marrow transplantation).
  • Participant has known infection with or history of being positive for virus (HBV) or virus (HCV) infection.
  • Presence of clinical or laboratory symptoms/signs of extramedullary myeloid malignancy.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
465 participants (actual)

Study arms

  • Experimental
    Part 1: Venetoclax + Azacitidine (AZA) + Best Supportive Care

    Participants will be administered various doses and dose regiments of venetoclax and AZA. Venetoclax will be administered once daily (QD) (Days 1-28) for up to 24 cycles, AZA QD on Days 1-5 of each 28-day cycle for up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days)

    Drug: Venetoclax · Drug: Azacitidine · Other: Best Supportive Care (BSC)

  • Experimental
    Part 2: Arm B - Best Supportive Care (BSC)

    Participants will receive treatment as prescribed by their physician according to the BSC for up to 24 cycles (1 cycle = 28 days)

    Other: Best Supportive Care (BSC)

  • Experimental
    Part 2: Arm A - Venetoclax + Azacitidine (AZA) + BSC

    Participants will be administered with venetoclax and AZA at a dose level determined in Part 1 in addition to best supportive care (when required). Venetoclax will be administered once daily (QD) (Days 1-28) for up to 24 cycles, AZA QD on Days 1-5 of each 28-day cycle for up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days).

    Drug: Venetoclax · Drug: Azacitidine · Other: Best Supportive Care (BSC)

Interventions

  • Tablet; Oral

    Also known as: ABT-199, GDC-0199, VENCLEXTA

  • Subcutaneous (SC) or intravenous (IV) injection

  • OtherBest Supportive Care (BSC)

    BSC is the best supportive care, without AML directed therapy, determined per the investigator and institutional guidelines.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities (DLTs) Following Administration of Venetoclax and Azacitidine (Part 1)

    DLTs were any of the hematologic, nonhematologic toxicities, adverse events (AEs) occurring following administration of venetoclax and AZA as described in the protocol and evaluated by the Investigator and the sponsor.

    Time frame: Up to 28 days

  2. Overall Survival (OS) (Part 2)

    OS was defined as the time from the date of randomization to the date of death from any cause.

    Time frame: Up to approximately 41 months

Secondary outcomes

  1. Morphologic Relapse-Free Survival (RFS) (Part 2)

    Morphologic relapse from AML was defined as bone marrow blasts of \>= 5% or reappearance of blasts in the peripheral blood not attributable to any other cause (e.g., bone marrow regeneration) in at least 2 peripheral blood samples at least one week apart or development of extramedullary disease after achieving a complete remission (CR) or complete remission with incomplete count recovery (CRi); or the date of death from any cause, whichever comes first as determined by the investigator.

    Time frame: Up to approximately 41 months

  2. Composite Relapse-Free Survival (RFS) (Part 2)

    Composite RFS was defined as the time from randomization from either morphologic relapse from AML, or non-morphologic relapse from AML, whichever comes first. Non-morphologic relapse from AML was defined as increase in disease burden determined by standard methods with reappearance or acquisition of new findings with or without change in anti-leukemic treatment per investigator decision due to cytogenetic abnormalities or change in molecular marker or measurable residual disease by multiparameter flow with sensitivity to at least 10\^-3; or the date of death from any cause, whichever came first as determined by the investigator.

    Time frame: Up to approximately 41 months

  3. Graft-versus-Host Disease (GvHD)-Free, Relapse Free Survival (GRFS) (Part 2)

    GRFS was defined as the time from the date of randomization to occurrence of disease relapse or incidence of GvHD or death from any cause.

    Time frame: Up to approximately 41 months

  4. Rate of Participants Without Higher Grade of GvHD (Part 2)

    Rate of Participants without higher grade of GvHD was defined as the percentage of participants without grade 2 or higher for acute graft-versus-host disease (aGvHD) and moderate/severe for chronic graft-versus-host disease (cGvHD) assessed by investigator at 90 days after randomization.

    Time frame: 90 days after randomization

  5. Change From Baseline in Physical Functioning Subscore as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) (Part 2)

    The EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales. The physical functioning score, reported here, ranged from 0 to 100, with a higher score indicating a better level of functioning. Positive changes from baseline indicate improvement.

    Time frame: Baseline, Month 6

  6. Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Cancer Fatigue Short Form (SF) 7a Score (Part 2)

    PROMIS Cancer Fatigue SF is a seven item questionnaire that assesses the impact and experience of fatigue over the past 7 days. All questions employ the following five response options: 1 = Not at all, 2 = A little bit, 3 = Somewhat, 4 = Quite a bit, and 5 = Very much. The total raw score is the sum of the responses to each question and is converted to a T-score. The T-score re-scales the total raw score to a standardized score with a mean of 50 and a standard deviation of 10. T-Scores range from 29.4 to 83.2, with higher scores indicating more fatigue. Negative changes from baseline indicate improvement.

    Time frame: Baseline, Month 6

  7. Percentage of Participants With Measurable Residual Disease (MRD) Conversion in Participants With MRD >= 10^-3 at Baseline (Part 2)

    MRD conversion rate was defined as the percentage of participants who convert to MRD \< 10\^-3 after initiation of treatment. The population for MRD analysis included participants whose bone marrow was MRD positive (\>=10\^-3, as determined by central flow cytometry) at baseline prior to randomization.

    Time frame: Up to approximately 41 months

  8. Time to Deterioration in Global Health Status (GHS)/Quality of Life (QoL) in Adult Participants (Part 2)

    Time to deterioration was defined as number of days from randomization to either deterioration of \>= 5 points based on the EORTC QLQ-C30 version 3 or death due to any cause. The GHS/QoL scale includes 2 questions in which participants were asked to rate their overall health and overall quality of life during the past week on a scale from 1 (very poor) to 7 (excellent). The 2 scores were averaged and transformed to a scale from 0 to 100, where a high score represents a high QoL.

    Time frame: Up to approximately 41 months

  9. Change From Baseline in European Quality-of-Life-5 Dimensional-5-Level (EQ-5D-5L) Score

    The EQ-5D-5L is a generic preference instrument that has been validated in numerous populations and has 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, each of which are rated on five levels of severity (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, 5: extreme problems) with higher scores representing higher symptom burden. A negative change from baseline indicates improvement in health status.

    Time frame: Baseline, Month 6

07

Results

Posted Jun 4, 2026
Limitations and caveats
This study was terminated due to strategic considerations.

Participant flow

Part 1
Participant flow — Part 1
MilestonePart 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QDPart 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QDPart 2: Best Supportive CarePart 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD
Started30500
Received at least 1 dose of study drug30500
Completed0000
Not completed30500
Withdrew: Withdrawal by subject1000
Withdrew: Death11300
Withdrew: Study terminated by sponsor18200
Part 2
Participant flow — Part 2
MilestonePart 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QDPart 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QDPart 2: Best Supportive CarePart 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD
Started00216214
Randomized to itt population00216214
Completed0000
Not completed00216214
Withdrew: Withdrawal by subject002512
Withdrew: Physician decision0001
Withdrew: Death004655
Withdrew: Study terminated by sponsor00142144
Withdrew: Other than specified0010
Withdrew: Lost to follow-up0022

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities (DLTs) Following Administration of Venetoclax and Azacitidine (Part 1)

DLTs were any of the hematologic, nonhematologic toxicities, adverse events (AEs) occurring following administration of venetoclax and AZA as described in the protocol and evaluated by the Investigator and the sponsor.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities (DLTs) Following Administration of Venetoclax and Azacitidine (Part 1)
ParticipantsPart 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QDPart 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QD
Number of Participants With Dose-Limiting Toxicities (DLTs) Following Administration of Venetoclax and Azacitidine (Part 1)30
PrimaryOverall Survival (OS) (Part 2)

OS was defined as the time from the date of randomization to the date of death from any cause.

Time frame:
Up to approximately 41 months
Reported as:
Median · months
Overall Survival (OS) (Part 2)
monthsPart 2: Best Supportive CarePart 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD
Overall Survival (OS) (Part 2)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Part 2: Best Supportive Care vs Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD · Stratified hazard ratio: 1.2 · 95% CI 0.81 to 1.77
SecondaryMorphologic Relapse-Free Survival (RFS) (Part 2)

Morphologic relapse from AML was defined as bone marrow blasts of \>= 5% or reappearance of blasts in the peripheral blood not attributable to any other cause (e.g., bone marrow regeneration) in at least 2 peripheral blood samples at least one week apart or development of extramedullary disease after achieving a complete remission (CR) or complete remission with incomplete count recovery (CRi); or the date of death from any cause, whichever comes first as determined by the investigator.

Time frame:
Up to approximately 41 months
Reported as:
Median · months
Morphologic Relapse-Free Survival (RFS) (Part 2)
monthsPart 2: Best Supportive CarePart 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD
Morphologic Relapse-Free Survival (RFS) (Part 2)NA (34.45 to NA)NA (NA to NA)
SecondaryComposite Relapse-Free Survival (RFS) (Part 2)

Composite RFS was defined as the time from randomization from either morphologic relapse from AML, or non-morphologic relapse from AML, whichever comes first. Non-morphologic relapse from AML was defined as increase in disease burden determined by standard methods with reappearance or acquisition of new findings with or without change in anti-leukemic treatment per investigator decision due to cytogenetic abnormalities or change in molecular marker or measurable residual disease by multiparameter flow with sensitivity to at least 10\^-3; or the date of death from any cause, whichever came first as determined by the investigator.

Time frame:
Up to approximately 41 months
Reported as:
Median · months
Composite Relapse-Free Survival (RFS) (Part 2)
monthsPart 2: Best Supportive CarePart 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD
Composite Relapse-Free Survival (RFS) (Part 2)NA (35.45 to NA)NA (NA to NA)
SecondaryGraft-versus-Host Disease (GvHD)-Free, Relapse Free Survival (GRFS) (Part 2)

GRFS was defined as the time from the date of randomization to occurrence of disease relapse or incidence of GvHD or death from any cause.

Time frame:
Up to approximately 41 months
Reported as:
Median · months
Graft-versus-Host Disease (GvHD)-Free, Relapse Free Survival (GRFS) (Part 2)
monthsPart 2: Best Supportive CarePart 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD
Graft-versus-Host Disease (GvHD)-Free, Relapse Free Survival (GRFS) (Part 2)11.1 (6.57 to 19.22)12.2 (8.31 to 24.94)
SecondaryRate of Participants Without Higher Grade of GvHD (Part 2)

Rate of Participants without higher grade of GvHD was defined as the percentage of participants without grade 2 or higher for acute graft-versus-host disease (aGvHD) and moderate/severe for chronic graft-versus-host disease (cGvHD) assessed by investigator at 90 days after randomization.

Time frame:
90 days after randomization
Reported as:
Number · percentage of participants
Rate of Participants Without Higher Grade of GvHD (Part 2)
percentage of participantsPart 2: Best Supportive CarePart 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD
Rate of Participants Without Higher Grade of GvHD (Part 2)63.4 (56.62 to 69.86)58.9 (51.97 to 65.54)
SecondaryChange From Baseline in Physical Functioning Subscore as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) (Part 2)

The EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales. The physical functioning score, reported here, ranged from 0 to 100, with a higher score indicating a better level of functioning. Positive changes from baseline indicate improvement.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · score on a scale
Change From Baseline in Physical Functioning Subscore as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) (Part 2)
score on a scalePart 2: Best Supportive CarePart 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD
Change From Baseline in Physical Functioning Subscore as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) (Part 2)5.29 ± 1.294.98 ± 1.23
SecondaryChange From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Cancer Fatigue Short Form (SF) 7a Score (Part 2)

PROMIS Cancer Fatigue SF is a seven item questionnaire that assesses the impact and experience of fatigue over the past 7 days. All questions employ the following five response options: 1 = Not at all, 2 = A little bit, 3 = Somewhat, 4 = Quite a bit, and 5 = Very much. The total raw score is the sum of the responses to each question and is converted to a T-score. The T-score re-scales the total raw score to a standardized score with a mean of 50 and a standard deviation of 10. T-Scores range from 29.4 to 83.2, with higher scores indicating more fatigue. Negative changes from baseline indicate improvement.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · score on a scale
Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Cancer Fatigue Short Form (SF) 7a Score (Part 2)
score on a scalePart 2: Best Supportive CarePart 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD
Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Cancer Fatigue Short Form (SF) 7a Score (Part 2)-1.5 ± 0.35-1.3 ± 0.34
SecondaryPercentage of Participants With Measurable Residual Disease (MRD) Conversion in Participants With MRD >= 10^-3 at Baseline (Part 2)

MRD conversion rate was defined as the percentage of participants who convert to MRD \< 10\^-3 after initiation of treatment. The population for MRD analysis included participants whose bone marrow was MRD positive (\>=10\^-3, as determined by central flow cytometry) at baseline prior to randomization.

Time frame:
Up to approximately 41 months
Reported as:
Number · percentage of participants
Percentage of Participants With Measurable Residual Disease (MRD) Conversion in Participants With MRD >= 10^-3 at Baseline (Part 2)
percentage of participantsPart 2: Best Supportive CarePart 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD
Percentage of Participants With Measurable Residual Disease (MRD) Conversion in Participants With MRD >= 10^-3 at Baseline (Part 2)39.7 (30.69 to 49.16)40.8 (31.95 to 50.18)
SecondaryTime to Deterioration in Global Health Status (GHS)/Quality of Life (QoL) in Adult Participants (Part 2)

Time to deterioration was defined as number of days from randomization to either deterioration of \>= 5 points based on the EORTC QLQ-C30 version 3 or death due to any cause. The GHS/QoL scale includes 2 questions in which participants were asked to rate their overall health and overall quality of life during the past week on a scale from 1 (very poor) to 7 (excellent). The 2 scores were averaged and transformed to a scale from 0 to 100, where a high score represents a high QoL.

Time frame:
Up to approximately 41 months
Reported as:
Median · months
Time to Deterioration in Global Health Status (GHS)/Quality of Life (QoL) in Adult Participants (Part 2)
monthsPart 2: Best Supportive CarePart 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD
Time to Deterioration in Global Health Status (GHS)/Quality of Life (QoL) in Adult Participants (Part 2)1.1 (1.08 to 1.84)1.6 (1.05 to 1.97)
SecondaryChange From Baseline in European Quality-of-Life-5 Dimensional-5-Level (EQ-5D-5L) Score

The EQ-5D-5L is a generic preference instrument that has been validated in numerous populations and has 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, each of which are rated on five levels of severity (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, 5: extreme problems) with higher scores representing higher symptom burden. A negative change from baseline indicates improvement in health status.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · score on a scale
Change From Baseline in European Quality-of-Life-5 Dimensional-5-Level (EQ-5D-5L) Score
score on a scalePart 2: Best Supportive CarePart 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD
mobility-0.00 ± 0.05-0.06 ± 0.05
self-care0.01 ± 0.040.02 ± 0.04
usual activities-0.09 ± 0.06-0.17 ± 0.06
pain/discomfort0.09 ± 0.060.02 ± 0.06
anxiety/depression0.10 ± 0.060.03 ± 0.05

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from the start of safety data collection to the end of the study. The median time on follow-up was 53.2, 60.2, 27.4, and 27.9 months for arms Part 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD, Part 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QD, Part 2: Best Supportive Care, and Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD, respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD12/30 (40%)9/30 (30%)30/30 (100%)
Part 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QD3/5 (60%)2/5 (40%)5/5 (100%)
Part 2: Best Supportive Care46/216 (21.3%)66/216 (30.6%)179/216 (82.9%)
Part 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD56/214 (26.2%)97/214 (45.3%)200/214 (93.5%)
Most frequent serious events
Showing 10 of 181
Most frequent serious events
EventPart 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QDPart 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QDPart 2: Best Supportive CarePart 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD
NEUTROPENIABlood and lymphatic system disorders0/301/50/2161/214
THROMBOCYTOPENIABlood and lymphatic system disorders0/301/50/2161/214
GRAFT VERSUS HOST DISEASEImmune system disorders0/301/51/2160/214
CYSTITISInfections and infestations0/301/50/2160/214
PNEUMONIAInfections and infestations0/301/512/21623/214
PLATELET COUNT DECREASEDInvestigations0/301/50/2162/214
CONFUSIONAL STATEPsychiatric disorders0/301/50/2160/214
HAEMATURIARenal and urinary disorders0/301/50/2160/214
DYSPNOEARespiratory, thoracic and mediastinal disorders0/301/50/2161/214
DIARRHOEAGastrointestinal disorders2/300/52/2163/214
Most frequent other events
Showing 10 of 85
Most frequent other events
EventPart 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QDPart 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QDPart 2: Best Supportive CarePart 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QD
NEUTROPENIABlood and lymphatic system disorders15/302/523/21682/214
NAUSEAGastrointestinal disorders14/302/528/21671/214
ALANINE AMINOTRANSFERASE INCREASEDInvestigations6/302/539/21643/214
THROMBOCYTOPENIABlood and lymphatic system disorders11/300/518/21661/214
NEUTROPHIL COUNT DECREASEDInvestigations6/300/525/21672/214
PLATELET COUNT DECREASEDInvestigations6/301/523/21672/214
DIARRHOEAGastrointestinal disorders9/301/537/21641/214
ANAEMIABlood and lymphatic system disorders8/301/533/21656/214
VOMITINGGastrointestinal disorders8/301/516/21652/214
FATIGUEGeneral disorders8/300/516/21643/214

Baseline characteristics

Age, Customized
Age, Customized(Participants)Part 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QDPart 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QDPart 2: Best Supportive CarePart 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QDTotal
< 1800325
>= 18 to < 65185162171356
>= 65 to < 75110473997
>= 7510427
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QDPart 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QDPart 2: Best Supportive CarePart 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QDTotal
Female1139079183
Male192126135282
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QDPart 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QDPart 2: Best Supportive CarePart 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QDTotal
Hispanic or Latino10131226
Not Hispanic or Latino295203202439
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QDPart 1: Venetoclax 200 mg QD 14 Days + Azacitidine 20 mg/m^2 QDPart 2: Best Supportive CarePart 2: Venetoclax 200 mg QD 28 Days + Azacitidine 20 mg/m^2 QDTotal
American Indian or Alaska Native00101
Asian518581172
Native Hawaiian or Other Pacific Islander00000
Black or African American00246
White244127127282
More than one race00101
Unknown or Not Reported10023
08

Study locations

165 sites
  • Arizona Oncology - Scottsdale - Cancer Transplant Institute /ID# 239711
    Scottsdale, Arizona 85258-4547, United States
  • University of Arizona Cancer Center - Tucson /ID# 242507
    Tucson, Arizona 85724, United States
  • University of Arkansas for Medical Sciences /ID# 239804
    Little Rock, Arkansas 72205, United States
  • City of Hope /ID# 213681
    Duarte, California 91010, United States
  • UCHSC Anschultz Cancer Pavilion /ID# 215618
    Aurora, Colorado 80045-2517, United States
  • Colorado Blood Cancer Institute /ID# 215980
    Denver, Colorado 80218, United States
  • Mayo Clinic Hospital Jacksonville /ID# 239710
    Jacksonville, Florida 32224, United States
  • AdventHealth Medical Group Blood & Marrow Transplant at Orlando /ID# 213985
    Orlando, Florida 32804-5505, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago /ID# 215840
    Chicago, Illinois 60611, United States
  • The University of Chicago Medical Center /ID# 215616
    Chicago, Illinois 60637-1443, United States
  • Loyola University Medical Ctr /ID# 215617
    Maywood, Illinois 60153, United States
  • Indiana Blood & Marrow Transpl /ID# 215842
    Indianapolis, Indiana 46237, United States
  • Duplicate_Ochsner Clinic Foundation-New Orleans /ID# 213834
    New Orleans, Louisiana 70121, United States
  • University of Maryland, Baltimore /ID# 213855
    Baltimore, Maryland 21201, United States
  • Massachusetts General Hospital /ID# 215765
    Boston, Massachusetts 02114, United States
  • Karmanos Cancer Institute - Dresner Clinic /ID# 214581
    Detroit, Michigan 48201-2013, United States
  • Masonic Cancer Center /ID# 239492
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic - Rochester /ID# 214685
    Rochester, Minnesota 55905-0001, United States
  • University of Mississippi Medical Center /ID# 239343
    Jackson, Mississippi 39216-4500, United States
  • The John Theurer Cancer /ID# 215251
    Hackensack, New Jersey 07601, United States
  • Roswell Park Cancer Institute /ID# 217857
    Buffalo, New York 14263, United States
  • Columbia University Medical Center /ID# 240875
    New York, New York 10032-3729, United States
  • Memorial Sloan Kettering Cancer Center-Koch Center /ID# 240680
    New York, New York 10065-6007, United States
  • Weill Cornell Medical College /ID# 214887
    New York, New York 10065, United States
  • Montefiore Medical Center - Moses Campus /ID# 241669
    The Bronx, New York 10467, United States
  • University of North Carolina /ID# 215814
    Chapel Hill, North Carolina 27514, United States
  • Atrium Health Wake Forest Baptist Medical Center /ID# 239210
    Winston-Salem, North Carolina 27157, United States
  • UC Health - Cincinnati /ID# 239263
    Cincinnati, Ohio 45267-2800, United States
  • University Hospitals Cleveland Medical Center /ID# 239260
    Cleveland, Ohio 44106, United States
  • University of Oklahoma, Stephenson Cancer Center /ID# 215611
    Oklahoma City, Oklahoma 73104-5418, United States
  • Oregon Health and Science University /ID# 215874
    Portland, Oregon 97239, United States
  • Penn State Hershey Medical Ctr /ID# 217120
    Hershey, Pennsylvania 17033-2360, United States
  • Children's Hospital of Philadelphia - Main /ID# 215410
    Philadelphia, Pennsylvania 19104-4319, United States
  • University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 214518
    Philadelphia, Pennsylvania 19104, United States
  • Duplicate_Allegheny General Hospital /ID# 216756
    Pittsburgh, Pennsylvania 15212, United States
  • UPMC Hillman Cancer Ctr /ID# 213715
    Pittsburgh, Pennsylvania 15232, United States
  • TriStar Centennial Medical Center /ID# 218750
    Nashville, Tennessee 37203-1551, United States
  • Texas Oncology - Medical City Dallas /ID# 216720
    Dallas, Texas 75230, United States
  • Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 213735
    Dallas, Texas 75246-2003, United States
  • Texas Transplant Institute /ID# 214691
    San Antonio, Texas 78229, United States
  • Virginia Commonwealth University Medical Center Main Hospital /ID# 239203
    Richmond, Virginia 23219, United States
  • Fred Hutchinson Cancer Research Center /ID# 214436
    Seattle, Washington 98109-1024, United States
  • Univ of Wisconsin Hosp/Clinics /ID# 216096
    Madison, Wisconsin 53792-0001, United States
  • The Kinghorn Cancer Centre /ID# 214660
    Darlinghurst, New South Wales 2010, Australia
  • Royal Adelaide Hospital /ID# 215678
    Adelaide, South Australia 5000, Australia
  • Peter MacCallum Cancer Ctr /ID# 214653
    Melbourne, Victoria 3000, Australia
  • The Alfred Hospital /ID# 240931
    Melbourne, Victoria 3004, Australia
  • Hospital de Clinicas de Porto Alegre /ID# 215042
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Hospital Amaral Carvalho - Fundacao Doutor Amaral Carvalho /ID# 215145
    Jaú, São Paulo 17210-070, Brazil
  • Hospital Nove de Julho /ID# 242359
    São Paulo, São Paulo 01409-001, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 239516
    São Paulo, 05403-000, Brazil
  • Vancouver Coastal Health Research Institute (VCHRI) /ID# 215363
    Vancouver, British Columbia V5Z 1M9, Canada
  • University Health Network_Princess Margaret Cancer Centre /ID# 215344
    Toronto, Ontario M5G 2M9, Canada
  • CIUSSS de l'est de l'Ile-de-Montreal - Hopital Maisonneuve-Rosemont /ID# 214591
    Montreal, Quebec H1T 2M4, Canada
  • Disc_Royal Victoria Hospital / McGill University Health Centre /ID# 215253
    Montreal, Quebec H4A 3J1, Canada
  • Saskatoon Cancer Centre /ID# 238821
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Peking University People's Hospital /ID# 215551
    Beijing, Beijing Municipality 100044, China
  • Chinese PLA General Hospital /ID# 216287
    Beijing, Beijing Municipality 100853, China
  • Aerospace Center Hospital /ID# 217018
    Beijing, Beijing Municipality 861059, China
  • Fujian Medical University Union Hospital /ID# 215555
    Fuzhou, Fujian 350001, China
  • Guangdong Provincial Peoples Hospital /ID# 218666
    Guangzhou, Guangdong 510080, China
  • Zhujiang Hospital of Southern Medical University /ID# 216333
    Guangzhou, Guangdong 510280, China
  • Nanfang Hospital of Southern Medical University /ID# 215553
    Guangzhou, Guangdong 510515, China
  • Shenzhen Second Peoples Hospital /ID# 239401
    Shenzhen, Guangdong 518039, China
  • Henan Cancer Hospital /ID# 215554
    Zhengzhou, Henan 450008, China
  • Tongji Hospital Tongji Medical College Huazhong University of Science and Techno /ID# 215552
    Wuhan, Hubei 430022, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 238373
    Wuhan, Hubei 430022, China
  • Xiangya Hospital Central South University /ID# 219025
    Changsha, Hunan 410008, China
  • Zhongda Hospital Southeast University /ID# 218926
    Nanjing, Jiangsu 210009, China
  • The First Affiliated Hospital of Soochow University /ID# 216605
    Suzhou, Jiangsu 215006, China
  • The Affiliated Hospital of Xuzhou Medical College /ID# 239098
    Xuzhou, Jiangsu 221006, China
  • The First Affiliated Hospital of Nanchang University /ID# 239168
    Nanchang, Jiangxi 330006, China
  • Shanghai Changhai Hospital /ID# 216334
    Shanghai, Shanghai Municipality 200433, China
  • Tangdu Hospital of The Fourth Military Medical University, PLA /ID# 216282
    Xi’an, Shanxi 710038, China
  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 215546
    Tianjin, Tianjin Municipality 300020, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 215550
    Hangzhou, Zhejiang 310003, China
  • Fakultní Nemocnice Brno - Jihlavská /ID# 214811
    Brno, Brno-mesto 625 00, Czechia
  • Fakultní nemocnice Hradec Králové - Sokolská /ID# 214814
    Hradec Králové, Hradec Kralove 500 05, Czechia
  • Fakultni Nemocnice Ostrava /ID# 239922
    Ostrava, Ostrava-mesto 708 52, Czechia
  • Ustav hematologie a krevni transfuze /ID# 215133
    Prague, 128 00, Czechia
  • Duplicate_CHU de Nice - Hôpital Archet 1 /ID# 214056
    Nice, Alpes-Maritimes 06200, France
  • Duplicate_CHU de Besancon - Jean Minjoz /ID# 241171
    Besançon, Doubs 25030, France
  • Duplicate_CHU Bordeaux - Hopital Haut Leveque /ID# 214055
    Pessac, Gironde 33604, France
  • CHRU Lille - Hopital Claude Huriez /ID# 217916
    Lille, Nord 59037, France
  • Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 214060
    Nantes, Pays de la Loire Region 44000, France
  • Hôpital Saint-Louis /ID# 214054
    Paris, 75010, France
  • AP-HP - Hopital Saint-Antoine /ID# 216957
    Paris, 75012, France
  • Hopital Pitie Salpetriere /ID# 241072
    Paris, Île-de-France Region 75013, France
  • Universitaetsklinik Heidelberg /ID# 216623
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Klinikum Augsburg /ID# 239583
    Augsburg, Bavaria 86156, Germany
  • Duplicate_Universitaetsklinikum Wuerzburg /ID# 215212
    Würzburg, Bavaria 97080, Germany
  • Medizinische Hochschule Hannover /ID# 214243
    Hanover, Lower Saxony 30625, Germany
  • Universitaetsklinikum Muenster /ID# 215213
    Münster, North Rhine-Westphalia 48149, Germany
  • Universitaetsklinikum Carl Gustav Carus Dresden /ID# 214244
    Dresden, Saxony 01307, Germany
  • Universitaetsklinikum Leipzig /ID# 245892
    Leipzig, Saxony 04103, Germany
  • Universitaetsklinikum Halle (Saale) /ID# 239585
    Halle, 06120, Germany
  • General Hospital of Athens Evangelismos /ID# 238810
    Athens, Attica 10676, Greece
  • University General Hospital Attikon /ID# 238812
    Athens, Attica 12462, Greece
  • University General Hospital of Patras /ID# 238811
    RION Patras Achaia, 26504, Greece
  • Debreceni Egyetem-Klinikai Kozpont /ID# 241123
    Debrecen, Hajdú-Bihar 4032, Hungary

Showing the first 100 of 165 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Sep 2025, 66 months.

Results were first posted in Jun 2026, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2019
First posted
Nov 13, 2019
StartActual
Feb 26, 2020
Primary completionActual
Sep 23, 2025
CompletionActual
Sep 23, 2025
Results first posted
Jun 4, 2026
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04161885
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 13, 2019
Start date
Feb 26, 2020
Primary completion
Sep 23, 2025
Completion
Sep 23, 2025
Results posted
Jun 4, 2026
Last update
Jun 4, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Azacitidine

Start the discussion